在RB1缺陷肺腺癌中,HDAC1修饰的细膜A/C驱动核变形
Hongxia Li1, Yu Chen2, Lihong Wei1
1Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China; Molecular Diagnosis and Gene Test Centre, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
损失RB1驱动肺癌的进展,导致细胞形状变化和核异常,可能通过HDAC1. 抑制HDAC1可能为TKI耐药肺腺癌提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 肺腺癌 (LUAD) 可以转化为小细胞肺癌 (SCLC) 作为对氨酸激酶抑制剂 (TKI) 的抵抗机制.
- 在LUAD血统转换和相关的形态变化中,RB1枯竭的作用尚不清楚.
研究的目的:
- 研究RB1枯竭驱动LUAD转化为SCLC的分子机制.
- 阐明RB1在形态变化的作用,包括上皮层-介质细胞过渡 (EMT) 和核异常.
主要方法:
- 在RB1缺陷的LUAD模型 (体外和体内) 中进行了综合分子,形态和结构分析.
- 在RB1/E2F1/HDAC1轴的功能性干扰和药物抑制.
主要成果:
- 减少RB1导致EMT特征和LUAD细胞中的核异常,与预后不佳相关.
- 鉴定出HDAC1是层层A/C修饰和核变形的关键调节者.
- 对HDAC1的药理抑制改善了RB1-贫乏细胞中的核异常.
结论:
- 通过HDAC1-介导的层状A/C脱乙烯化,RB1的下调促进LUAD形态变化 (EMT,核异常).
- 针对RB1或HDAC1可能是TKI耐药LUAD的治疗策略.
- 这些发现有助于患者分层和治疗晚期肺癌的治疗策略.
更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
Nuclear Stability
To hold positively charged protons together...
Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
Plastic Deformations
Plastic Deformations
Non-nuclear Inheritance
Nuclear Export of mRNA
